Guillain-Barre Syndrome (GBS) Market Size & Share Report, 2032

Guillain-Barre Syndrome (GBS) Market - By Treatment Type (First-line [IVIG, Plasma Exchange], Supportive), Type (Acute & Chronic Inflammatory Demyelinating Polyneuropathy, Miller Fisher Syndrome), Gender, Age Group, End-user – Global Forecast (2024 – 2032)

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Increasing incidence of GBS

3.2.1.2&nbsp;&nbsp;&nbsp; Growing awareness for rare disease treatment

3.2.1.3&nbsp;&nbsp;&nbsp; Government supporting policies and funding

3.2.1.4&nbsp;&nbsp;&nbsp; Expanding R&amp;D investment

3.2.1.5&nbsp;&nbsp;&nbsp; Advancements in diagnostics and treatment

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp; Adverse effects of treatments

3.2.2.2&nbsp;&nbsp;&nbsp; Regulatory and reimbursement challenges

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Pipeline analysis

3.5&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.7&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.3&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.4&nbsp;&nbsp;&nbsp; Strategy outlook matrix

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Treatment Type, 2021 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; First-line treatment

5.2.1&nbsp;&nbsp;&nbsp; Intravenous immunoglobulin (IVIG)

5.2.2&nbsp;&nbsp;&nbsp; Plasma exchange (Plasmapheresis)

5.3&nbsp;&nbsp;&nbsp; Supportive treatment

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Type, 2021 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Acute inflammatory demyelinating polyneuropathy (AIDP)

6.3&nbsp;&nbsp;&nbsp; Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

6.4&nbsp;&nbsp;&nbsp; Miller fisher syndrome (MFS)

6.5&nbsp;&nbsp;&nbsp; Acute motor axonal neuropathy (AMAN)

6.6&nbsp;&nbsp;&nbsp; Other types

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Gender, 2021 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Male

7.3&nbsp;&nbsp;&nbsp; Female

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Age Group, 2021 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Below 20 years

8.3&nbsp;&nbsp;&nbsp; 21-40 years

8.4&nbsp;&nbsp;&nbsp; 41-59 years

8.5&nbsp;&nbsp;&nbsp; 60 and above

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End-user, 2021 &ndash; 2032 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; Hospitals

9.3&nbsp;&nbsp;&nbsp; Clinics

9.4&nbsp;&nbsp;&nbsp; Rehabilitation centers

9.5&nbsp;&nbsp;&nbsp; Other end-users

Chapter 10&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 &ndash; 2032 ($ Mn)

10.1&nbsp;&nbsp;&nbsp; Key trends

10.2&nbsp;&nbsp;&nbsp; North America

10.2.1&nbsp;&nbsp;&nbsp;U.S.

10.2.2&nbsp;&nbsp;&nbsp;Canada

10.3&nbsp;&nbsp;&nbsp; Europe

10.3.1&nbsp;&nbsp;&nbsp;Germany

10.3.2&nbsp;&nbsp;&nbsp;UK

10.3.3&nbsp;&nbsp;&nbsp;France

10.3.4&nbsp;&nbsp;&nbsp;Spain

10.3.5&nbsp;&nbsp;&nbsp;Italy

10.3.6&nbsp;&nbsp;&nbsp;Netherlands

10.3.7&nbsp;&nbsp;&nbsp;Rest of Europe

10.4&nbsp;&nbsp;&nbsp; Asia Pacific

10.4.1&nbsp;&nbsp;&nbsp;Japan

10.4.2&nbsp;&nbsp;&nbsp;China

10.4.3&nbsp;&nbsp;&nbsp;India

10.4.4&nbsp;&nbsp;&nbsp;Australia

10.4.5&nbsp;&nbsp;&nbsp;South Korea

10.4.6&nbsp;&nbsp;&nbsp;Rest of Asia Pacific

10.5&nbsp;&nbsp;&nbsp; Latin America

10.5.1&nbsp;&nbsp;&nbsp;Brazil

10.5.2&nbsp;&nbsp;&nbsp;Mexico

10.5.3&nbsp;&nbsp;&nbsp;Rest of Latin America

10.6&nbsp;&nbsp;&nbsp; Middle East and Africa

10.6.1&nbsp;&nbsp;&nbsp;Saudi Arabia

10.6.2&nbsp;&nbsp;&nbsp;South Africa

10.6.3&nbsp;&nbsp;&nbsp;UAE

10.6.4&nbsp;&nbsp;&nbsp;Rest of Middle East and Africa

Chapter 11&nbsp;&nbsp;&nbsp;Company Profiles

11.1&nbsp;&nbsp;&nbsp; AbbVie Inc.

11.2&nbsp;&nbsp;&nbsp; Biogen Inc.

11.3&nbsp;&nbsp;&nbsp; Cadila Healthcare Limited

11.4&nbsp;&nbsp;&nbsp; CSL Behring LLC

11.5&nbsp;&nbsp;&nbsp; F.Hoffmann-La Roche Ltd.

11.6&nbsp;&nbsp;&nbsp; GSK plc

11.7&nbsp;&nbsp;&nbsp; Grifols SA

11.8&nbsp;&nbsp;&nbsp; LGM Pharmaceuticals, Inc.

11.9&nbsp;&nbsp;&nbsp; Merck &amp; Co., Inc.

11.10&nbsp;&nbsp;&nbsp; Octapharma AG

11.11&nbsp;&nbsp;&nbsp; Pfizer Inc.

11.12&nbsp;&nbsp;&nbsp; Takeda Pharmaceutical Company Limited 
&nbsp;

GuillainBarre Syndrome GBS Market

Get a free sample of this report